An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) will webcast the Exelixis 2023 R&D Day: Science & Strategy event on December 12, 2023, featuring speakers reviewing the company’s research and development pipeline, clinical updates, and efforts to serve more cancer patients and generate sustainable value for shareholders.
Positive
None.
Negative
None.
ALAMEDA, Calif.--(BUSINESS WIRE)--
Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST. During the event, featured speakers will review the progress of the company’s growing research and development pipeline, highlight recent clinical updates and elaborate on the company’s continued efforts to serve more patients with cancer and generate sustainable, long-term value for shareholders.
The event will be livestreamed and can be accessed via EXELRDDay.com. The registration access code is: EXELScience&Strategy. The webcast of the event will also be available at www.exelixis.com on the Event Calendar page under the Investors & News heading for one year.
AboutExelixis
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.
Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.
When is the Exelixis 2023 R&D Day: Science & Strategy event taking place?
The event will take place on Tuesday, December 12, 2023.
What time will the event be held?
The event will be held from 9:00 a.m. to 12:30 p.m. EST.
How can I access the event?
The event will be livestreamed and can be accessed via EXELRDDay.com with the registration access code: EXELScience&Strategy. It will also be available at www.exelixis.com on the Event Calendar page under the Investors & News heading for one year.
What will be discussed during the event?
Featured speakers will review the progress of the company’s research and development pipeline, highlight recent clinical updates, and elaborate on the company’s efforts to serve more patients with cancer and generate sustainable, long-term value for shareholders.
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
